regulatory approval of a drug or medical device, and may be interventional, observational or 12 preclinical.
13
A collaboration requires appropriate process and governance frameworks to be established in 14 order to be successful. Important considerations include the routes for submitting a request, support the utilization of a product for a recommending body or advisory committee (e.g., The
14
Advisory Committee on Immunization Practices ("ACIP")).
15
Interventional studies 16 Collaborative Research has been most readily adopted in oncology and HIV therapy areas, both Importantly, it is the non-industry partner that will be the regulatory sponsor and will initiate 5 and take responsibility for the clinical trial.
11
The sponsor holds the appropriate regulatory should also be aligned with standards of the industry partner. interventional research, which can make the lead collaborator more difficult to differentiate.
5
Therefore, when an observational study is conducted using a Collaborative Research model, it is 6 especially important that the respective roles and responsibilities of the industry and non-7 industry partners are clearly defined upfront and outlined in the contract.
8
It is important for the non-industry sponsor to maintain responsibility for all aspects of the 9 collaboration, or to document clearly the justification for the industry collaborator taking on 10 specific responsibilities (e.g., preclinical expertise in sample analysis). Regulation (GDPR) requirements) and adverse event reporting. When engaging in regional or should also be prepared to respond to the industry collaborator in case of regulatory authority 8 queries once the data are submitted.
9
As explained above, once aligned on the intent and purpose of the research, it is important to 10 understand and establish the expected roles and responsibilities of each party. Will any 11 responsibilities be delegated to a third party and, if so, is the third party qualified to do the 12 work? What oversight will be put in place and how frequently will it occur? Who will be 13 responsible for data analysis and the development of the study report? For example, in the 14 case of a regulatory submission, the industry partner may be best placed to draft the clinical 15 study report, in order to ensure that the requirements set forth by the agencies are met. with all Pharmacovigilance requirements and data privacy regulations. 
